Navigation Links
BMP Sunstone Reports Third Quarter 2009 Financial Results
Date:11/9/2009

n in the first nine months of 2008. The EPS calculation is based on 48.2 million diluted shares outstanding, compared to 39.4 million diluted shares outstanding in the prior year period.

Financial Guidance

Due to slower than expected growth rates in the second quarter of 2009, today BMP Sunstone is adjusting revenue, adjusted EBITDA and non-GAAP net income guidance for the fiscal year 2009. The Company now expects revenue to reach $140 million to $150 million, adjusted EBITDA to reach $12 million to $13 million, and non-GAAP net income to reach $6 million to $7 million.

Today's revisited guidance is down from previous full year expectations of $150 million to $160 million in revenue, $16 million to $18 million in adjusted EBITDA, and $9 million to $11 million in non-GAAP net income.

Gao continued, "We believe that declines in purchases from distributors hit a low point during the second quarter, improved during the third quarter, and should noticeably improve when the pending Chinese healthcare policies are finalized and disclosed. Our 2009 financial guidance reflects sales and marketing expansion in China resulting from continued performance at all of our business units, especially at Sunstone and Beijing Med-Pharm."

Conference Call

The Company will hold a conference call at 5:00 pm ET on November 9, 2009 to discuss third quarter 2009 results. Listeners may access the call by dialing 1-888-713-4211 or +1-617-213-4864 for international callers, access code: 20626681. Preregistration and a webcast will be available through the Company's website at http://www.bmpsunstone.com . A replay of the call will be

accessible through November 16, 2009 by dialing 1-888-286-8010 or +1-617-801-6888 for international callers, access code: 24243405.

About BMP Sunstone Corporation

BMP Sunstone Corporat
'/>"/>

SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
2. BMP Sunstone Receives Import Drug License (IDL) from SFDA
3. BMP Sunstone Corporation Appoints Zhiqiang Han to President and Chief Operating Officer
4. BMP Sunstone Reports Second Quarter 2008 Financial Results
5. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
6. BMP Sunstone Announces Participation in September Investor Conference
7. BMP Sunstone Announces Participation in November Investor Conferences
8. BMP Sunstone Reports Third Quarter 2008 Financial Results
9. BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesdays Call
10. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
11. BMP Sunstone to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... , ... A newly launched business plan contest will ask startup companies from ... life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and ... of expert mentorship from a senior industry figure drawn from the Pistoia Alliance membership. ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that ... in Philadelphia, PA. , The presentation took place on Tuesday, June 16 ... for the development of APX3330 for the treatment of pancreatic cancer. A copy ...
(Date:7/1/2015)... 2015  UCB, a multinational biopharmaceutical company, and ... in designing, transforming, and running intelligent business operations, ... of their close collaboration in driving transformation that ... services (GBS) finance organization. The Aecus ... work together effectively to embrace the innovative promise ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5
... Iowa Patricia Thiel of Iowa State University and the Ames ... of coasters to the middle and a trinket box to the ... lots of little things." So Thiel grabbed the smaller things and ... box. "Nature wants one big thing all together, like this." ...
... 2010 Cannabis Science, Inc. (OTC Bulletin Board: ... pharmaceutical cannabis products announced today that regardless of the ... electoral issues throughout the country, it is apparent that ... more important than ever, as the demand for the ...
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that the Company was awarded four separate ... Project, enacted as part of the Patient Protection and ... is a benefit targeted to small business therapeutic discovery ...
Cached Biology Technology:Iowa State, Ames Laboratory scientists advance the understanding of the big getting bigger 2Proposition 19 Decision Prompts Cannabis Science to Anticipate Increased Demand for its Pharmaceutical Products for Critical Ailments and Begin the Formal Application Process for FDA Clinical Trials Immediately 2Proposition 19 Decision Prompts Cannabis Science to Anticipate Increased Demand for its Pharmaceutical Products for Critical Ailments and Begin the Formal Application Process for FDA Clinical Trials Immediately 3PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000 2PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000 3
(Date:6/30/2015)... -- Genisphere announced Tom Bliss ... develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss comes ... of the last 25 years in leadership positions at ... & Johnson. Tom started his career in Investment Banking, ... He graduated from Dartmouth College with a BA in ...
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
(Date:6/24/2015)... Calif. , June 24, 2015  Synaptics ... of human interface solutions, today announced that Sharp ... to provide secure authentication for its latest flagship ... reached more than 200 million shipments of its ... Sharp reinforces Synaptics, strength, scalability and leadership in ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... Lymphoma Protected by SPAK Silencing A group led ... of the protein SPAK may contribute to B-cell lymphoma development. ... issue of the American Journal of Pathology . ... system cancers. Epigenetic changes, such as DNA hypermethylation, may ...
... Consortium (PGSC), an international team of scientists from industry ... sequence of the potato genome with the help of ... horticulture in the College of Agriculture and Life Sciences ... potato variety that accelerated the development of a blueprint ...
... 2009Using clever chemistry, a Scripps Research team has pinpointed ... the progression of the devastating disease Friedreich,s ataxia in ... findings, developed in collaboration with scientists from Repligen Corporation, ... human clinical trials, which will be a welcome event ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Draft potato genome based on unique potato variety 2Mechanism for potential Friedreich's ataxia drug uncovered 2Mechanism for potential Friedreich's ataxia drug uncovered 3
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
... The Genome Sequencer 20 System revolutionizes ... massively parallel fashion. The Genome Sequencer ... accessories Reagents and consumables for library ... for mapping and de novo assembly ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
... Human serum is obtained from normal human ... by a test for Human Immunodeficiency Virus ... Virus (Anti-HIV 1/2), Hepatitis C Virus (HCV), ... (HbsAg) and Non-reactive by a screening test ...
Biology Products: